|
|
Post by agedhippie on Jul 26, 2021 12:03:41 GMT -5
samples are a big expense but absolutely needed for this product . The RoI on samples is huge. I did the numbers for this when Mike was complaining about giving out samples. There is a reason every insulin manufacturer except Afrezza showers samples on patients and doctors. Right now I am using Tresiba as my basal insulin having swapped from Lantus via Toujeo. At every point all I had to do was say I was thinking of swapping to have pens dumped on me. This is the drug dealer approach. People don't change insulin often so once you have them hooked they are staying with you for years, and given the price of insulin in the US that's a license to print money. That box of Afrezza or pens is chump change in the scheme of things. |
|
|
|
Post by nylefty on Sept 21, 2021 15:46:42 GMT -5
Tsunami=25,000,000 million patients now will have access to Afrezza... Making friends of CGM makers..which can now..co-promote...hmm Is it July 18th yet? Still waiting for that "Tsunami". It still remains the case that hardly any patients on Medicare have access to Afrezza, unless they pay out of pocket. Alas. |
|
|
|
Post by MnkdWASmyRtrmntPlan on Sept 22, 2021 13:21:11 GMT -5
Right, NYL. July 18th, 202?
|
|
|
|
Post by nylefty on Jan 24, 2022 20:55:26 GMT -5
Tsunami=25,000,000 million patients now will have access to Afrezza... Making friends of CGM makers..which can now..co-promote...hmm Is it July 18th yet? Still waiting for that "Tsunami". It still remains the case that hardly any patients on Medicare have access to Afrezza, unless they pay out of pocket. Alas. Still waiting for that "Tsunami" when "Medicare" will supposedly cover Afrezza. Just checked my Aetna Medicare Advantage plan and it still lists Afrezza under "non-covered prescriptions." |
|
|
|
Post by prcgorman2 on Jan 25, 2022 8:01:22 GMT -5
Is it July 18th yet? Still waiting for that "Tsunami". It still remains the case that hardly any patients on Medicare have access to Afrezza, unless they pay out of pocket. Alas. Still waiting for that "Tsunami" when "Medicare" will supposedly cover Afrezza. Just checked my Aetna Medicare Advantage plan and it still lists Afrezza under "non-covered prescriptions." It does beg the question what is the definition of “Medicare coverage”? In researching the answer I found a Medicare FAQ where I learned some Medicare Advantage plans do not even offer drug coverage, and an Advantage plan may also prevent purchasing supplementary Part D coverage (I think). Here’s the link to the Medicare FAQ: www.medicare.gov/sites/default/files/2021-07/11109-Medicare-Drug-Coverage-Guide_0.pdfAnyway, from the FAQ... “All Medicare drug coverage must give at least a standard level of coverage set by Medicare. However, plans offer different combinations of coverage and cost sharing. Plans offering Medicare drug coverage may differ in the drugs they cover, how much you have to pay, and which pharmacies you can use.” And your point may be, “what good does it do to be covered under Medicare if the insurers do not actually cover it?” And, that’s a good point. In my opinion, it just takes us back to the two leading challenges remaining to effectively marketing Afrezza are that more studies are needed to convince prescribers that, “Afrezza IS THE SAFE CHOICE”, and that insurers must cover the drug at par with RAAs and that won’t happen unless insurers are either convinced they will save money by covering Afrezza or more likely will get deep discounts to put Afrezza coverage costs at par with RAAs. |
|
|
|
Post by sr71 on Jan 25, 2022 10:43:32 GMT -5
Part D insurance providers have no incentive to cover drugs that will lower the overall cost of healthcare.
This is because Part D only pays for the cost of drugs, but not for doctor visits, lab work, and hospitalizations.
The profit for Part D providers is from the kickbacks paid by the pharmacy benefit providers (PBM's).
Until this issue is remedied, the US will continue to have extremely high healthcare costs, less than best-in-class drug coverage, and poor patient outcomes.
In short, patients and the taxpayers pay for this parabolic catastrophe with their lives and/or hard-earned money, while the Part D providers and PBM's profit handsomely.
|
|
